RU2263512C2 - Средства, подавляющие отторжение трансплантата - Google Patents

Средства, подавляющие отторжение трансплантата Download PDF

Info

Publication number
RU2263512C2
RU2263512C2 RU2003129166/15A RU2003129166A RU2263512C2 RU 2263512 C2 RU2263512 C2 RU 2263512C2 RU 2003129166/15 A RU2003129166/15 A RU 2003129166/15A RU 2003129166 A RU2003129166 A RU 2003129166A RU 2263512 C2 RU2263512 C2 RU 2263512C2
Authority
RU
Russia
Prior art keywords
ailim
pharmaceutical composition
transplantation
antibody
human
Prior art date
Application number
RU2003129166/15A
Other languages
English (en)
Russian (ru)
Other versions
RU2003129166A (ru
Inventor
Сейити СУЗУКИ (JP)
Сейити СУЗУКИ
Мицуаки ИСОБЕ (JP)
Мицуаки ИСОБЕ
Original Assignee
Джапан Тобакко, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Джапан Тобакко, Инк. filed Critical Джапан Тобакко, Инк.
Publication of RU2003129166A publication Critical patent/RU2003129166A/ru
Application granted granted Critical
Publication of RU2263512C2 publication Critical patent/RU2263512C2/ru

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Surgery (AREA)
  • Transplantation (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Graft Or Block Polymers (AREA)
  • External Artificial Organs (AREA)
  • Cylinder Crankcases Of Internal Combustion Engines (AREA)
  • Soil Working Implements (AREA)
  • Transplanting Machines (AREA)
RU2003129166/15A 2001-03-01 2002-02-05 Средства, подавляющие отторжение трансплантата RU2263512C2 (ru)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
JP2001056209 2001-03-01
JP2001056216 2001-03-01
JP2001-56209 2001-03-01
JP2001-56216 2001-03-01
JP2002008028 2002-01-16
JP2002-8028 2002-01-16
PCT/JP2002/000930 WO2002070010A1 (fr) 2001-03-01 2002-02-05 Inhibiteurs de rejet du greffon

Publications (2)

Publication Number Publication Date
RU2003129166A RU2003129166A (ru) 2005-03-10
RU2263512C2 true RU2263512C2 (ru) 2005-11-10

Family

ID=27346134

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2003129166/15A RU2263512C2 (ru) 2001-03-01 2002-02-05 Средства, подавляющие отторжение трансплантата

Country Status (24)

Country Link
US (2) US7438905B2 (https=)
EP (2) EP1769807B1 (https=)
JP (1) JP4212278B2 (https=)
KR (1) KR100609444B1 (https=)
CN (1) CN1518458B (https=)
AT (2) ATE352318T1 (https=)
AU (1) AU2002228435B2 (https=)
BR (1) BR0207787A (https=)
CA (1) CA2439858C (https=)
CY (1) CY1110143T1 (https=)
CZ (1) CZ20032406A3 (https=)
DE (2) DE60235928D1 (https=)
DK (1) DK1769807T3 (https=)
ES (1) ES2344219T3 (https=)
HU (2) HU228045B1 (https=)
IL (2) IL156845A0 (https=)
MX (1) MXPA03006736A (https=)
NO (2) NO331690B1 (https=)
NZ (1) NZ527076A (https=)
PT (1) PT1769807E (https=)
RU (1) RU2263512C2 (https=)
SI (1) SI1769807T1 (https=)
SK (1) SK288048B6 (https=)
WO (1) WO2002070010A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2549701C2 (ru) * 2007-05-07 2015-04-27 Медиммун, Ллк Анти-icos антитела и их применение в лечении онкологических, связанных с трансплантацией и аутоиммунных заболеваний

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3521382B2 (ja) 1997-02-27 2004-04-19 日本たばこ産業株式会社 細胞間接着及びシグナル伝達を媒介する細胞表面分子
US7112655B1 (en) 1997-02-27 2006-09-26 Japan Tobacco, Inc. JTT-1 protein and methods of inhibiting lymphocyte activation
DE19821060A1 (de) * 1997-09-23 1999-04-15 Bundesrepublik Deutschland Let Ko-stimulierendes Polypeptid von T-Zellen, monoklonale Antikörper sowie die Herstellung und deren Verwendung
JP4210454B2 (ja) 2001-03-27 2009-01-21 日本たばこ産業株式会社 炎症性腸疾患治療剤
JP3871503B2 (ja) 1999-08-30 2007-01-24 日本たばこ産業株式会社 免疫性疾患治療剤
CN1411373A (zh) * 1999-12-16 2003-04-16 特瓦制药工业有限公司 制备来氟米特的新方法和新晶形的来氟米特
JP3597140B2 (ja) 2000-05-18 2004-12-02 日本たばこ産業株式会社 副刺激伝達分子ａｉｌｉｍに対するヒトモノクローナル抗体及びその医薬用途
JP4212278B2 (ja) 2001-03-01 2009-01-21 日本たばこ産業株式会社 移植片拒絶反応抑制剤
RU2291675C2 (ru) * 2004-07-09 2007-01-20 Институт теоретической и экспериментальной биофизики РАН Способ обработки трансплантатов для сердечно-сосудистой хирургии
GB0504544D0 (en) * 2005-03-04 2005-04-13 Novartis Ag Organic compounds
JP2006321765A (ja) * 2005-05-20 2006-11-30 Mikiko Ueda 肝移植における拒絶反応の予防又は治療薬、或いは拒絶反応とは断定できない肝機能異常の治療薬
US9931386B2 (en) * 2008-06-16 2018-04-03 Atsuo Ochi Recombinant multiple domain fusion protein mitogens and use thereof for inducing enhancement or repression of antigen-specific immunity
US20120114595A1 (en) * 2009-07-16 2012-05-10 Otsuka Chemical Co., Ltd. Sugar chain-added ailim extracellular domain and method for producing same
US9420770B2 (en) 2009-12-01 2016-08-23 Indiana University Research & Technology Corporation Methods of modulating thrombocytopenia and modified transgenic pigs
WO2011130322A1 (en) * 2010-04-12 2011-10-20 University Of Miami Macroporous bioengineered scaffolds for cell transplantation
ES2612914T3 (es) * 2011-03-31 2017-05-19 Inserm - Institut National De La Santé Et De La Recherche Médicale Anticuerpos dirigidos contra Icos y usos de los mismos
US20150139994A1 (en) * 2013-11-12 2015-05-21 The Regents Of The University Of California Compositions and methods for preventing allogeneic immune rejection
NZ719724A (en) * 2013-11-22 2022-08-26 Takeda Pharmaceuticals Co Methods of treating antibody-mediated rejection in organ transplant patients with c1-esterase inhibitor
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
CN109207580B (zh) 2014-03-12 2022-03-11 西奈山伊坎医学院 鉴定处于慢性损伤风险的肾异体移植物接受者的方法
WO2015200887A2 (en) 2014-06-26 2015-12-30 Icahn School Of Medicine At Mount Sinai Method for diagnosing subclinical and clinical acute rejection by analysis of predictive gene sets
US10308985B2 (en) * 2014-06-26 2019-06-04 Icahn School Of Medicine At Mount Sinai Methods for diagnosing risk of renal allograft fibrosis and rejection
MA41414A (fr) 2015-01-28 2017-12-05 Centre Nat Rech Scient Protéines de liaison agonistes d' icos
TWI704154B (zh) 2015-12-03 2020-09-11 英商葛蘭素史克智慧財產發展有限公司 新穎化合物
WO2017098421A1 (en) 2015-12-08 2017-06-15 Glaxosmithkline Intellectual Property Development Limited Benzothiadiazine compounds
WO2017153952A1 (en) 2016-03-10 2017-09-14 Glaxosmithkline Intellectual Property Development Limited 5-sulfamoyl-2-hydroxybenzamide derivatives
JP2019510802A (ja) 2016-04-07 2019-04-18 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ タンパク質調節物質として有用な複素環アミド
HRP20220936T1 (hr) 2016-04-07 2022-10-28 Glaxosmithkline Intellectual Property Development Limited Heterociklički amidi korisni kao modulatori proteina
CA3023157A1 (en) 2016-05-05 2017-11-09 Glaxosmithkline Intellectual Property (No.2) Limited Enhancer of zeste homolog 2 inhibitors
US9567399B1 (en) 2016-06-20 2017-02-14 Kymab Limited Antibodies and immunocytokines
WO2018029474A2 (en) 2016-08-09 2018-02-15 Kymab Limited Anti-icos antibodies
KR102379464B1 (ko) 2016-06-20 2022-03-29 키맵 리미티드 항-pd-l1 항체
JP2019521166A (ja) 2016-07-20 2019-07-25 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ Ｐｅｒｋ阻害剤としてのイソキノリン誘導体
KR20260030924A (ko) 2016-08-09 2026-03-06 키맵 리미티드 항-icos 항체
EP3534947A1 (en) 2016-11-03 2019-09-11 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses & methods
EP3585782A1 (en) 2017-02-27 2020-01-01 GlaxoSmithKline Intellectual Property Development Limited Heterocyclic amides as kinase inhibitors
BR112019025913A2 (pt) 2017-06-09 2020-06-30 Glaxosmithkline Intellectual Property Development Limited métodos para tratar câncer em um paciente em necesssidade do mesmo e para produzir um anticorpo, anticorpo anti-icos ou fragmento de ligação ao antígeno do mesmo e um anticorpo anti-ox40 ou fragmento de ligação ao antígeno do mesmo, uso de um anticorpo anti-icos ou porção de ligação ao antígeno do mesmo e um anticorpo anti-ox40 ou porção de ligação ao antígeno do mesmo na fabricação de um medicamento, polinucleotídeo que codifica um anticorpo, vetor, e, célula hospedeira.
EP3634483A1 (en) 2017-06-09 2020-04-15 GlaxoSmithKline Intellectual Property Development Limited Combination therapy
EP3635010A1 (en) 2017-06-09 2020-04-15 GlaxoSmithKline Intellectual Property Development Limited Combination therapy with icos agonist and ox40 agonist to treat cancer
GB201709808D0 (en) 2017-06-20 2017-08-02 Kymab Ltd Antibodies
WO2019021208A1 (en) 2017-07-27 2019-01-31 Glaxosmithkline Intellectual Property Development Limited USEFUL INDAZOLE DERIVATIVES AS PERK INHIBITORS
WO2019053617A1 (en) 2017-09-12 2019-03-21 Glaxosmithkline Intellectual Property Development Limited CHEMICAL COMPOUNDS
CN111094353A (zh) 2017-09-14 2020-05-01 葛兰素史密斯克莱知识产权发展有限公司 用于癌症的组合治疗
CA3077337A1 (en) 2017-10-05 2019-04-11 Glaxosmithkline Intellectual Property Development Limited Modulators of stimulator of interferon genes (sting)
US20210238172A1 (en) 2017-10-05 2021-08-05 Glaxosmithkline Intellectual Property Development Limited Heterocyclic amides useful as protein modulators and methods of using the same
EP3728314A1 (en) 2017-12-19 2020-10-28 Kymab Limited Bispecific antibody for icos and pd-l1
GB201721338D0 (en) 2017-12-19 2018-01-31 Kymab Ltd Anti-icos Antibodies
RU2688172C1 (ru) * 2018-04-05 2019-05-20 Государственное бюджетное учреждение здравоохранения Московской области "Московский областной научно-исследовательский клинический институт им. М.Ф. Владимирского" (ГБУЗ МО МОНИКИ им. М.Ф. Владимирского) Способ профилактики отторжения трансплантата трупной почки
ES3037279T3 (en) 2018-04-16 2025-09-30 Icahn School Med Mount Sinai Method and kits for prediction of acute rejection and renal allograft loss using pre-transplant transcriptomic signatures in recipient blood
GB201807924D0 (en) 2018-05-16 2018-06-27 Ctxt Pty Ltd Compounds
EP3801615A1 (en) 2018-05-31 2021-04-14 GlaxoSmithKline Intellectual Property Development Ltd Combined therapy with icos binding proteins and argininemethyltransferase inhibitors
BR112020023451A2 (pt) 2018-05-31 2021-02-23 Glaxosmithkline Intellectual Property Development Limited terapia combinada
WO2020031087A1 (en) 2018-08-06 2020-02-13 Glaxosmithkline Intellectual Property Development Limited Combination therapy
JP2022513374A (ja) 2018-10-22 2022-02-07 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド 投薬
US20200368369A1 (en) * 2019-05-22 2020-11-26 Wyvern Pharmaceuticals Inc. Composition for endogenous production of checkpoint protein precursors
GB201910305D0 (en) 2019-07-18 2019-09-04 Ctxt Pty Ltd Compounds
GB201910304D0 (en) 2019-07-18 2019-09-04 Ctxt Pty Ltd Compounds
WO2021018941A1 (en) 2019-07-31 2021-02-04 Glaxosmithkline Intellectual Property Development Limited Methods of treating cancer
WO2021046289A1 (en) 2019-09-06 2021-03-11 Glaxosmithkline Intellectual Property Development Limited Dosing regimen for the treatment of cancer with an anti icos agonistic antibody and ipilimumab
WO2021043961A1 (en) 2019-09-06 2021-03-11 Glaxosmithkline Intellectual Property Development Limited Dosing regimen for the treatment of cancer with an anti icos agonistic antibody and chemotherapy
JP7280387B2 (ja) 2019-09-27 2023-05-23 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド 抗原結合タンパク質
CN114981265B (zh) 2019-12-18 2025-01-03 Ctxt私人有限公司 化合物
CN113294813B (zh) * 2020-02-24 2022-09-02 宁波方太厨具有限公司 一种电磁灶
AU2021256925A1 (en) 2020-04-14 2022-11-03 Ares Trading S.A. Combination treatment for cancer based upon an ICOS antibody and a PD-L1 antibody TGF-beta-receptor fusion protein
AU2021256652A1 (en) 2020-04-14 2022-11-03 Glaxosmithkline Intellectual Property Development Limited Combination treatment for cancer involving anti-ICOS and anti-PD1 antibodies, optionally further involving anti-tim3 antibodies
AU2021257570A1 (en) 2020-04-14 2022-11-03 Glaxosmithkline Intellectual Property Development Limited Combination treatment for cancer
GB202007099D0 (en) 2020-05-14 2020-07-01 Kymab Ltd Tumour biomarkers for immunotherapy
CN116917273A (zh) 2021-03-02 2023-10-20 葛兰素史克知识产权发展有限公司 作为dnmt1抑制剂的经取代的吡啶
JP2024511831A (ja) 2021-03-31 2024-03-15 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド 抗原結合タンパク質およびそれらの組み合わせ
US20220396623A1 (en) 2021-05-18 2022-12-15 Kymab Limited Uses of anti-icos antibodies
GB202107994D0 (en) 2021-06-04 2021-07-21 Kymab Ltd Treatment of cancer
US20250340641A1 (en) 2022-05-18 2025-11-06 Kymab Limited Uses of anti-icos antibodies

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998019706A1 (en) * 1996-11-08 1998-05-14 Idec Pharmaceuticals Corporation Identification of unique binding interactions between certain antibodies and the human b7.1 and b7.2 co-stimulatory antigens
WO1998038216A1 (en) * 1997-02-27 1998-09-03 Japan Tobacco Inc. Cell surface molecule mediating cell adhesion and signal transmission
RU2130782C1 (ru) * 1991-06-11 1999-05-27 Сентер Фор Блад Рисерч, Инк. Рекомбинантная молекула днк, кодирующая молекулу iсам-3, молекула адгезии iсам-3, антитело, способное связываться с такой молекулой, фармацевтическая композиция

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5506126A (en) 1988-02-25 1996-04-09 The General Hospital Corporation Rapid immunoselection cloning method
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6641809B1 (en) 1990-03-26 2003-11-04 Bristol-Myers Squibb Company Method of regulating cellular processes mediated by B7 and CD28
US5770197A (en) 1991-06-27 1998-06-23 Bristol-Myers Squibb Company Methods for regulating the immune response using B7 binding molecules and IL4-binding molecules
JP3162438B2 (ja) 1991-09-12 2001-04-25 住友製薬株式会社 高感度特異的抗体測定法
US5484892A (en) 1993-05-21 1996-01-16 Dana-Farber Cancer Institute, Inc. Monoclonal antibodies that block ligand binding to the CD22 receptor in mature B cells
US6719972B1 (en) * 1994-06-03 2004-04-13 Repligen Corporation Methods of inhibiting T cell proliferation or IL-2 accumulation with CTLA4- specific antibodies
US5747461A (en) 1994-07-26 1998-05-05 Markov; Angel K. Synergistic administration of cyclosporine and fructose diphosphate
IL125255A (en) 1996-01-23 2002-02-10 Genentech Inc Anti-cd18 antibodies for treating stroke
US5914112A (en) 1996-01-23 1999-06-22 Genentech, Inc. Anti-CD18 antibodies in stroke
CZ293926B6 (cs) 1996-09-18 2004-08-18 Zetesisás@Áp@Áa Farmaceutický prostředek
WO1998037415A1 (en) 1997-02-20 1998-08-27 The Regents Of The University Of California ULCERATIVE COLITIS pANCA SECRETORY VESICLE ANTIGEN AND METHODS OF USING SAME
FI107538B (fi) * 1997-02-26 2001-08-31 Raisio Benecol Oy Menetelmä stanoliesterien valmistamiseksi
US7112655B1 (en) * 1997-02-27 2006-09-26 Japan Tobacco, Inc. JTT-1 protein and methods of inhibiting lymphocyte activation
WO2001018022A1 (en) 1999-09-03 2001-03-15 Human Genome Sciences, Inc. 52 human secreted proteins
JP3957765B2 (ja) 1997-04-07 2007-08-15 ジェネンテク・インコーポレイテッド 抗ｖｅｇｆ抗体
US7259247B1 (en) * 1997-09-23 2007-08-21 Bundersrespublik Deutschaland Letztvertreten Durch Den Direktor Des Robert-Koch-Institutes Anti-human T-cell costimulating polypeptide monoclonal antibodies
DE19821060A1 (de) 1997-09-23 1999-04-15 Bundesrepublik Deutschland Let Ko-stimulierendes Polypeptid von T-Zellen, monoklonale Antikörper sowie die Herstellung und deren Verwendung
JPH11228442A (ja) * 1998-02-09 1999-08-24 Cypros Pharmaceut Corp 臓器移植後のシクロスポリン投与量を低減するためのフルクトース二リン酸の使用
JP2000154151A (ja) * 1998-09-14 2000-06-06 Kyo Jo 免疫抑制剤
AU767241B2 (en) 1998-09-14 2003-11-06 Qiang Xu Immunosuppressive agents
WO2000019988A1 (en) 1998-10-07 2000-04-13 Millennium Pharmaceuticals, Inc. NOVEL Th2-SPECIFIC MOLECULES AND USES THEREOF
DK1149114T3 (da) * 1999-02-03 2014-06-23 Amgen Inc Polypeptider, der er involveret ved et immunrespons
BR0010711A (pt) 1999-05-06 2002-02-13 Genetics Inst Uso de moléculas co-estimulatórias solúveis para intensificar respostas imunes
AU6615500A (en) 1999-07-28 2001-02-19 Genetics Institute Inc. Preventing immune-mediated abortion by inhibiting costimulation
AU6458400A (en) 1999-08-11 2001-03-13 Isis Innovation Limited Nucleic acid, polypeptides, assays, therapeutic methods and means
JP4210454B2 (ja) 2001-03-27 2009-01-21 日本たばこ産業株式会社 炎症性腸疾患治療剤
JP3871503B2 (ja) * 1999-08-30 2007-01-24 日本たばこ産業株式会社 免疫性疾患治療剤
PT1218504E (pt) 1999-09-21 2007-10-22 Genetics Inst Llc Novas moléculas gl50 e suas utilizações
EP1224201A4 (en) 1999-10-29 2005-03-02 Human Genome Sciences Inc 32 HUMAN SECRETED PROTEINS
WO2001064704A1 (en) 2000-03-02 2001-09-07 Mayo Foundation For Medical Education And Research hB7-H2, A NOVEL CO-STIMULATORY MOLECULE
JP3597140B2 (ja) * 2000-05-18 2004-12-02 日本たばこ産業株式会社 副刺激伝達分子ａｉｌｉｍに対するヒトモノクローナル抗体及びその医薬用途
AU1796902A (en) 2000-11-28 2002-06-11 Amgen Inc Novel polypeptides involved in immune response
JP4212278B2 (ja) 2001-03-01 2009-01-21 日本たばこ産業株式会社 移植片拒絶反応抑制剤

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2130782C1 (ru) * 1991-06-11 1999-05-27 Сентер Фор Блад Рисерч, Инк. Рекомбинантная молекула днк, кодирующая молекулу iсам-3, молекула адгезии iсам-3, антитело, способное связываться с такой молекулой, фармацевтическая композиция
WO1998019706A1 (en) * 1996-11-08 1998-05-14 Idec Pharmaceuticals Corporation Identification of unique binding interactions between certain antibodies and the human b7.1 and b7.2 co-stimulatory antigens
WO1998038216A1 (en) * 1997-02-27 1998-09-03 Japan Tobacco Inc. Cell surface molecule mediating cell adhesion and signal transmission

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2549701C2 (ru) * 2007-05-07 2015-04-27 Медиммун, Ллк Анти-icos антитела и их применение в лечении онкологических, связанных с трансплантацией и аутоиммунных заболеваний

Also Published As

Publication number Publication date
NO20110218L (no) 2003-11-03
ATE463256T1 (de) 2010-04-15
ATE352318T1 (de) 2007-02-15
HK1102293A1 (en) 2007-11-16
NO20033839L (no) 2003-11-03
DK1769807T3 (da) 2010-07-19
US20040253229A1 (en) 2004-12-16
SK12142003A3 (sk) 2004-05-04
HU228108B1 (en) 2012-11-28
CN1518458B (zh) 2010-05-26
US7438905B2 (en) 2008-10-21
CA2439858C (en) 2009-07-14
ES2344219T3 (es) 2010-08-20
EP1769807A1 (en) 2007-04-04
DE60235928D1 (de) 2010-05-20
NZ527076A (en) 2006-03-31
EP1374901B1 (en) 2007-01-24
NO331690B1 (no) 2012-02-27
IL156845A (en) 2011-10-31
BR0207787A (pt) 2004-03-23
CA2439858A1 (en) 2002-09-12
EP1769807B1 (en) 2010-04-07
WO2002070010A1 (fr) 2002-09-12
AU2002228435B2 (en) 2005-03-10
CZ20032406A3 (cs) 2004-10-13
JP4212278B2 (ja) 2009-01-21
EP1374901B9 (en) 2007-11-07
DE60217839T2 (de) 2007-11-15
DE60217839D1 (de) 2007-03-15
SI1769807T1 (sl) 2010-08-31
CN1518458A (zh) 2004-08-04
RU2003129166A (ru) 2005-03-10
HK1061531A1 (en) 2004-09-24
MXPA03006736A (es) 2004-05-31
IL156845A0 (en) 2004-02-08
US20090047292A1 (en) 2009-02-19
EP1374901A1 (en) 2004-01-02
PT1769807E (pt) 2010-06-02
SK288048B6 (sk) 2013-03-01
HUP0303332A2 (hu) 2003-12-29
HU228045B1 (en) 2012-09-28
EP1374901A4 (en) 2004-09-15
KR20030078946A (ko) 2003-10-08
KR100609444B1 (ko) 2006-08-03
NO20033839D0 (no) 2003-08-29
JP2003277293A (ja) 2003-10-02
CY1110143T1 (el) 2015-01-14

Similar Documents

Publication Publication Date Title
RU2263512C2 (ru) Средства, подавляющие отторжение трансплантата
RU2203682C2 (ru) Фармацевтическая композиция для лечения иммунных заболеваний
RU2281118C2 (ru) Средства для лечения воспалительных кишечных заболеваний
JPH09501824A (ja) モノクローナル抗体の免疫抑制活性および毒性のモジュレーションのための方法ならびに物質
HK1102293B (en) Graft rejection suppressors
HK1061531B (en) Graft rejection suppressors
ZA200306516B (en) Graft rejection inhibitors.

Legal Events

Date Code Title Description
MM4A The patent is invalid due to non-payment of fees

Effective date: 20150206